Cancer immunotherapy resistance: The impact of microbiome-derived short-chain fatty acids and other emerging metabolites

Hersi, Fatema; Elgendy, Sara M.; Shamma, Salma A. Al; Atell, Roa T.; Sadiek, Omar; Omar, Hany A.

doi:10.1016/j.lfs.2022.120573

Cited by 7 publications

(5 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transplantation of fecal microbiota or commensal microbes significantly improved the efficacy of ICBs (267, 268). Notably, oral administration of SCFAs exhibits obvious benefits against cancers suggesting part of the regulatory mechanism of gut microbiota and host immune response (269). As accumulating immune therapeutic strategies are now approved in the clinical treatment of CRC, the role of SCFAs in colorectal cancer immunotherapies would be another interesting topic worth further investigation.…”

Section: Molecular Mechanisms Of Postbiotics Against Colorectal Cance...mentioning

confidence: 99%

Beneficial insights into postbiotics against colorectal cancer

Song

Wang

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most prevalent and life-threatening cancer types with limited therapeutic options worldwide. Gut microbiota has been recognized as the pivotal determinant in maintaining gastrointestinal (GI) tract homeostasis, while dysbiosis of gut microbiota contributes to CRC development. Recently, the beneficial role of postbiotics, a new concept in describing microorganism derived substances, in CRC has been uncovered by various studies. However, a comprehensive characterization of the molecular identity, mechanism of action, or routes of administration of postbiotics, particularly their role in CRC, is still lacking. In this review, we outline the current state of research toward the beneficial effects of gut microbiota derived postbiotics against CRC, which will represent the key elements of future precision-medicine approaches in the development of novel therapeutic strategies targeting gut microbiota to improve treatment outcomes in CRC.

show abstract

Section: Molecular Mechanisms Of Postbiotics Against Colorectal Cance...mentioning

confidence: 99%

Beneficial insights into postbiotics against colorectal cancer

Song

Wang

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

show abstract

“…It is due to the assumption that the SCFAs blood levels can reflect the development and/or progression of the pathology (especially cancer diseases). Moreover, approximately 95% of SCFAs are absorbed from the colon, so the complex view of the influence of microbiota-associated metabolites on an organism demands the quantification of these molecules both in faeces and in the blood, however according to the literature the content of the colon represents a better option ( 90 , 99 , 113 , 114 ). The blood samples should be processed as soon as possible after the blood collection and the resulting plasma or serum sample should be stored at -80°C.…”

Section: Analysis Of Scfasmentioning

confidence: 99%

Determination of short-chain fatty acids as putative biomarkers of cancer diseases by modern analytical strategies and tools: a review

et al. 2023

View full text Add to dashboard Cite

Short-chain fatty acids (SCFAs) are the main metabolites produced by bacterial fermentation of non-digestible carbohydrates in the gastrointestinal tract. They can be seen as the major flow of carbon from the diet, through the microbiome to the host. SCFAs have been reported as important molecules responsible for the regulation of intestinal homeostasis. Moreover, these molecules have a significant impact on the immune system and are able to affect inflammation, cardiovascular diseases, diabetes type II, or oncological diseases. For this purpose, SCFAs could be used as putative biomarkers of various diseases, including cancer. A potential diagnostic value may be offered by analyzing SCFAs with the use of advanced analytical approaches such as gas chromatography (GC), liquid chromatography (LC), or capillary electrophoresis (CE) coupled with mass spectrometry (MS). The presented review summarizes the importance of analyzing SCFAs from clinical and analytical perspective. Current advances in the analysis of SCFAs focused on sample pretreatment, separation strategy, and detection methods are highlighted. Additionally, it also shows potential areas for the development of future diagnostic tools in oncology and other varieties of diseases based on targeted metabolite profiling.

show abstract

“…This paper has focused on SCFAs, as they are likely the most widely understood and studied bacterial metabolites, however other key classes of metabolites may also be useful research targets in the future for their role in enhancing cancer treatment efficacy and toxicity. For instance, inosine, tryptophan metabolites (Indole-3carboxaldehyde), and secondary bile acids have been found to improve immunotherapy outcomes [ 133 , 134 ]. Further, these metabolites may provide protection against therapy-related toxicities [ 72 , 135 ].…”

Section: Targeting Scfa To Improve Cancer Treatment Outcomesmentioning

confidence: 99%

Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities

et al. 2022

View full text Add to dashboard Cite

The gut microbiota has emerged as a key modulator of cancer treatment responses in terms of both efficacy and toxicity. This effect is clearly mediated by processes impacting the activation and modulation of immune responses. More recently, the ability to regulate chemotherapeutic drug metabolism has also emerged as a key driver of response, although the direct mechanisms have yet to be fully elucidated. Through fermentation, the gut microbiota can produce several types of metabolites, including short-chain fatty acids (SCFAs). SCFAs play an important role in maintaining epithelial barrier functions and intestinal homeostasis, with recent work suggesting that SCFAs can modulate response to cancer treatments and influence both anti-tumor immune response and inflammatory-related side effects. In this review, we will discuss the importance of SCFAs and their implications for cancer treatment response and toxicities.

show abstract

Cancer immunotherapy resistance: The impact of microbiome-derived short-chain fatty acids and other emerging metabolites

Cited by 7 publications

References 133 publications

Beneficial insights into postbiotics against colorectal cancer

Beneficial insights into postbiotics against colorectal cancer

Determination of short-chain fatty acids as putative biomarkers of cancer diseases by modern analytical strategies and tools: a review

Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities

Contact Info

Product

Resources

About